GLP-1 Medications for Weight Loss Now Available!

There are currently 44 active clinical trials seeking participants for Overweight research studies. The states with the highest number of trials for Overweight participants are California, Texas, Florida and New York.
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Valley Clinical Trials, Inc., Northridge, California +26 locations
Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
Recruiting
Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults wi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Overweight, Obesity
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/20/2025
Locations: CenExel iResearch, LLC, Decatur, Georgia +32 locations
Conditions: Obesity, Overweight
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Cullman Clinical Trials - Family Medicine, Cullman, Alabama +24 locations
Conditions: Overweight, Type 2 Diabetes, Obesity
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +11 locations
Conditions: Obesity, Overweight
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Recruiting
The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight/obesity crisis in another at-risk, low socioeconomic status (SES) population, taxi and for-hire vehicle (FHV) drivers (Lyft, Uber, etc.). ROADMAP also utilizes an effectiveness- implementation hybrid type 1 design. Hybrid trials, which blend effectiveness and implementation studies,... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/08/2025
Locations: Mexican Consulate's Ventanilla de Salud (VDS), New York, New York
Conditions: Overweight, Overweight and Obesity, Overweight or Obesity, Obesity, Obese
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Juno Research, LLC, Houston, Texas
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity
Recruiting
This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chanc... Read More
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
05/02/2025
Locations: Celerion, Lincoln, Lincoln, Nebraska
Conditions: Overweight, Obesity
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Recruiting
Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how fat cells are metabolized. Eligibility: People ages 18-60 who: * Are black or Hispanic * Weigh more than 110 pounds * Have a body mass index of 25-40 * Do not have a condition that requires drug treatment Design: Partic... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteers, Overweight
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
Recruiting
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take par... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/27/2025
Locations: Master Centre for USA, Plainsboro, New Jersey +37 locations
Conditions: Overweight, Obesity
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Sansum Diabetes Research Institute, Goleta, California +147 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +53 locations
Conditions: Obesity, Overweight